John Strickler

John Strickler, MD is a Professor of Medicine in the Division of Medical Oncology, where he is Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute, Leader of the Molecular Tumor Board, and Associate Director of Clinical Research – GI Oncology. Dr. Strickler’s clinic specializes on the treatment of gastrointestinal malignancies, with a particular emphasis on gastroesophageal, pancreatic, and colorectal cancers. His research focuses on precision cancer medicine: identification of biomarkers that predict sensitivity or resistance to targeted therapies and immunotherapy. He has designed and executed clinical trials that test novel therapies and innovative therapeutic strategies. He was Principal Investigator on an investigator sponsored trial that led to the first FDA-approved therapy for HER2+ metastatic colorectal cancer. He has first-author publications in several high impact factor medical journals, including the New England Journal of Medicine, Clinical Cancer Research, Cancer Discovery, Journal of Clinical Oncology, and Lancet Oncology. Nationally, he has served as a member of the American Society of Clinical Oncology (ASCO) Treatment Guidelines Committee for Advanced Colon Cancer.